Tarsus Pharmaceuticals In... (TARS)

NASDAQ: TARS · Real-Time Price · USD

50.40

-1.51 (-2.91%)

At close: May 01, 2025, 3:55 PM

50.30

-0.20%

After-hours: May 01, 2025, 04:01 PM EDT

-2.91% (1D)

Bid	45
Market Cap	2.1B
Revenue (ttm)	182.95M
Net Income (ttm)	-115.55M
EPS (ttm)	-3.07
PE Ratio (ttm)	-16.42
Forward PE	41.9
Analyst	Buy

Ask	53.89
Volume	775,670
Avg. Volume (20D)	664,925.2
Open	51.74
Previous Close	51.91
Day's Range	49.43 - 53.89
52-Week Range	20.08 - 57.28
Beta	0.94

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; a...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 323

Stock Exchange NASDAQ

Ticker Symbol TARS

Website https://www.tarsusrx.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for TARS stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 30.95% from the latest price.

Stock Forecasts

Next Earnings Release

Tarsus Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-9.33%

Shares of Tarsus Pharmaceuticals are trading lower... Unlock content with Pro Subscription

5 months ago

+0.3%

Tarsus Pharmaceuticals shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $63 to $65.

News

21 hours ago · zacks.com

Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?

The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

1 month ago · seekingalpha.com

Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project T...

2 months ago · seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwa...

2 months ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago.